Gene Yao provides clients with a multifaceted national and international practice in the areas of biotech, chemical and pharmaceutical intellectual property law and pharmaceutical regulatory law. Gene notably served as in-house patent counsel for a major pharmaceutical company, which gives him a unique perspective when dealing with the issues his clients face on a daily basis.
Gene’s practice includes virtually all aspects of IP law, including domestic and international patent preparation and prosecution, patent enforcement and litigation, counseling, opinion rendering, due diligence, post-grant patent practice, IP licensing, agreement work, and patent portfolio management.
Gene has counseled biotech, chemical and pharmaceutical clients on a variety of issues. He has experience in a number of technological areas, including small and large molecule pharmaceuticals, genomics, proteomics, therapeutic antibodies, therapeutic biologics, gene therapies, recombinant DNA, antimicrobial therapies, immunoassays, formulations, pharmaceutical compounding, transgenic animals, diagnostics, personalized health care, medical devices, fertilizers, polymers, cleaning materials and cosmetics.
Additionally, Gene has represented clients on pharmaceutical regulatory matters such as drug product exclusivities, investigational new drug applications, new drug applications and abbreviated new drug applications, safe harbor, biosimilars, Hatch-Waxman issues and Orange Book patent matters.
Gene has also counseled on other matters of relevance to the pharmaceutical industry, including life-cycle management and target clearance.
Gene is a former senior counsel at Roche Pharmaceuticals, where he was the primary U.S. patent attorney in the metabolic and cardiovascular diseases and disorders therapeutic areas. He also counseled in the oncology and central nervous system areas.